Literature DB >> 27973711

Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts the risk of HBV-related liver cancer development.

Seung Up Kim1,2, Ja Yoon Heo1, Beom Kyung Kim1,2, Jun Yong Park1,2, Do Young Kim1,2, Kwang-Hyub Han1,2, Sang Hoon Ahn1,2, Hyon-Suk Kim3.   

Abstract

BACKGROUND & AIMS: Wisteria floribunda agglutinin-positive human Mac-2 binding protein (WFA+ -M2BP) can be used to assess the degree of liver fibrosis, but few studies have investigated its prognostic utility. We evaluated whether serum WFA+ -M2BP can predict the development of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients.
METHODS: A total of 1323 CHB patients with WFA+ -M2BP test results between 2009 and 2011 were included in this retrospective analysis.
RESULTS: The mean age of patients (793 men) was 51.0 years. During the follow-up period (median 60.3 months), 52 (3.9%) patients developed HCC. Age, the proportion of male gender, the presence of diabetes and cirrhosis, and levels of aspartate aminotransferase, alpha-foetoprotein, and WFA+ -M2BP were significantly greater in patients with HCC than in those without HCC, whereas serum albumin levels and platelet counts were significantly lower in patients with HCC than in those without HCC (all P<.05). In multivariate analysis, WFA+ -M2BP level was an independent predictor of HCC development (adjusted hazard ratio 1.143, 95% CI: 1.139-1.829), along with male gender and diabetes (all P<.05). In patients without cirrhosis (n=1087), WFA+ -M2BP levels ≥1.8 were associated with a higher risk of HCC development (P<.001 by log-rank test), whereas WFA+ -M2BP levels ≥1.8 tended to be associated with a higher risk of HCC development in patients with cirrhosis (n=236) (P=.073 by log-rank test).
CONCLUSIONS: WFA+ -M2BP level can independently predict HCC development. Further studies should investigate whether WFA+ -M2BP level could be incorporated into surveillance strategies for CHB patients.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Mac-2 binding protein; hepatitis B; hepatocellular carcinoma; liver fibrosis

Mesh:

Substances:

Year:  2016        PMID: 27973711     DOI: 10.1111/liv.13341

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  15 in total

Review 1.  Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis.

Authors:  Ken Shirabe; Yuki Bekki; Dolgormaa Gantumur; Kenichiro Araki; Norihiro Ishii; Atsushi Kuno; Hisashi Narimatsu; Masashi Mizokami
Journal:  J Gastroenterol       Date:  2018-01-09       Impact factor: 7.527

2.  Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B.

Authors:  Kazunori Kawaguchi; Masao Honda; Hajime Ohta; Takeshi Terashima; Tetsuro Shimakami; Kuniaki Arai; Taro Yamashita; Yoshio Sakai; Tatsuya Yamashita; Eishiro Mizukoshi; Takuya Komura; Masashi Unoura; Shuichi Kaneko
Journal:  J Gastroenterol       Date:  2017-08-28       Impact factor: 7.527

3.  High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues.

Authors:  Noboru Shinkai; Masanori Nojima; Etsuko Iio; Kayoko Matsunami; Hidenori Toyoda; Shuko Murakami; Takako Inoue; Shintaro Ogawa; Takashi Kumada; Yasuhito Tanaka
Journal:  J Gastroenterol       Date:  2017-12-29       Impact factor: 7.527

4.  Serum Levels of M2BPGi as Short-Term Predictors of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B Patients.

Authors:  Jessica Liu; Hui-Han Hu; Mei-Hsuan Lee; Masaaki Korenaga; Chin-Lan Jen; Richard Batrla-Utermann; Sheng-Nan Lu; Li-Yu Wang; Masashi Mizokami; Chien-Jen Chen; Hwai-I Yang
Journal:  Sci Rep       Date:  2017-10-30       Impact factor: 4.379

5.  Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts liver cancer development in chronic hepatitis B patients under antiviral treatment.

Authors:  Ka-Shing Cheung; Wai-Kay Seto; Danny Ka-Ho Wong; Lung-Yi Mak; Ching-Lung Lai; Man-Fung Yuen
Journal:  Oncotarget       Date:  2017-07-18

Review 6.  Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases.

Authors:  Nobuharu Tamaki; Masayuki Kurosaki; Rohit Loomba; Namiki Izumi
Journal:  Ann Lab Med       Date:  2020-08-25       Impact factor: 3.464

7.  Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy.

Authors:  Tai-Chung Tseng; Cheng-Yuan Peng; Yao-Chun Hsu; Tung-Hung Su; Chia-Chi Wang; Chun-Jen Liu; Hung-Chih Yang; Wan-Ting Yang; Chia-Hsin Lin; Ming-Lung Yu; Hsueh-Chou Lai; Yasuhito Tanaka; Mindie H Nguyen; Chen-Hua Liu; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Liver Cancer       Date:  2020-01-10       Impact factor: 11.740

Review 8.  Novel biomarkers for the management of chronic hepatitis B.

Authors:  Takako Inoue; Yasuhito Tanaka
Journal:  Clin Mol Hepatol       Date:  2020-06-15

Review 9.  Candidate Biomarkers of Liver Fibrosis: A Concise, Pathophysiology-oriented Review.

Authors:  Mattia Bellan; Luigi Mario Castello; Mario Pirisi
Journal:  J Clin Transl Hepatol       Date:  2018-07-02

Review 10.  Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update.

Authors:  James Lok; Kosh Agarwal
Journal:  Viruses       Date:  2021-07-10       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.